Aanpak van het gemetastaseerd niercelcarcinoom, een veranderend paradigma

Delen via:

Log hier in om volledige toegang te krijgen.

Login of Account maken

 



Bronnen:

  1. Low G, Huang G, Fu W, Moloo Z, Girgis S. Review of renal cell carcinoma and its common subtypes in radiology. World J Radiol. 2016;8:484-500. doi: 10.4329/wjr.v8.i5.484.,Chen F, Zhang Y, Şenbabaoğlu Y, et al. Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Cell Rep. 2016;14:2476-89. doi: 10.1016/j.celrep.2016.02.024. Epub 2016 Mar 3.,Afriansyah A, Hamid AR, Mochtar CA, Umbas R. Targeted Therapy for Metastatic Renal Cell Carcinoma. Acta Med Indones. 2016 Oct;48:335-47.,Rini BI, Bellmunt J, Clancy J, et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol. 2014;32:752-9. doi: 10.1200/JCO.2013.50.5305.,Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369:722-31. doi: 10.1056/NEJMoa1303989.,Hutson TE, Lesovoy V, Al-Shukri S, et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol. 2013;14:1287-94. doi: 10.1016/S1470-2045(13)70465-0. Epub 2013 Oct 25.,Hudes G, Carducci M, Tomczak P, et al; Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271-81.,Escudier B, Eisen T, Stadler WM, et al; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-34. Erratum in: N Engl J Med. 2007;357:203.,Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013;14:552-62. doi: 10.1016/S1470-2045(13)70093-7. Epub 2013 Apr 16.,Motzer RJ, Escudier B, Oudard S, et al; RECORD‐1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer. 2010;116:4256-65. doi: 10.1002/cncr.25219.,Choueiri TK, Escudier B, Powles T, et al; METEOR Investigators. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373:1814-23. doi: 10.1056/NEJMoa1510016. Epub 2015 Sep 25.,Motzer RJ, Escudier B, McDermott DF, et al; CheckMate 025 Investigators. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373:1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25.,Hutson TE, Escudier B, Esteban E, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32:760-7. doi: 10.1200/JCO.2013.50.3961.,Eichelberg C, Vervenne WL, De Santis M, et al. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer. Eur Urol. 2015;68:837-47. doi: 10.1016/j.eururo.2015.04.017. Epub 2015 May 4.

Er zijn geen nieuwsberichten gevonden.
Er zijn geen webcasts gevonden.
Er zijn geen e-learnings gevonden.
Er zijn geen bijeenkomsten gevonden.
Er zijn geen posts gevonden.
Er zijn geen podcasts gevonden.